Product Definition and Formulation Logic
Bupivacaine liposome injection is a long-acting amide local anesthetic. Traditional bupivacaine injections typically provide less than 8 hours of pain relief. In contrast, bupivacaine liposome injection is a long-acting sustained-release formulation that uses DepoFoam technology to encapsulate bupivacaine in multivesicular liposomes. After injection, bupivacaine is gradually released as the liposome vesicles break open. Each vesicle releases a limited amount of drug, but the cumulative effect of multiple vesicles breaking at different times extends the release duration. This mechanism enables bupivacaine to provide pain relief for up to 72 hours, far surpassing the 6 to 8 hours typically offered by traditional local anesthetics.

This liposome injection offers sustained pain relief with a single dose, eliminating the need for additional equipment such as catheters and pain pumps. This simplifies medical procedures, enhances patient comfort and compliance, and reduces equipment costs. Bupivacaine liposome injection provides a more convenient and effective solution for postoperative pain management.

According to the market research report “Global Bupivacaine Liposome Injection Market Report 2024–2030,” published by QYResearch, the global market size is projected to grow from USD 538.75 million in 2023 to USD 907.30 million by 2030, at a CAGR of 8.60% during the forecast period.

The formulation’s clinical value is inseparable from the opioid-sparing imperative in postoperative care. A single injection that delivers three days of analgesia can reduce or eliminate the need for systemic opioids, which carry risks of respiratory depression, sedation, and dependence. The economic argument follows: a higher-priced local anesthetic may be cost-effective if it reduces opioid-related adverse events, shortens hospital stays, or enables earlier discharge. This calculus varies by procedure type and reimbursement structure, which explains why adoption is uneven across surgical specialties.

Competitive Landscape: Duopoly and the DepoFoam Barrier
Global key manufacturers of bupivacaine liposome injection include Pacira Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals. In 2022, Jiangsu Hengrui Pharmaceuticals obtained approval for marketing in China, becoming the world’s first generic version of this product. In China, besides Hengrui, Kelun Pharmaceutical and Zhejiang Sundoc Pharmaceutical have also entered this market. In October 2024, Kelun’s subsidiary, Hunan Kelun Pharmaceutical, received approval for its bupivacaine liposome injection, considered equivalent to passing consistency evaluation, making it the second approved product in China.

The competitive structure is defined by the formulation technology rather than the molecule. Conventional bupivacaine is off-patent and widely manufactured; the liposomal encapsulation—specifically the DepoFoam multivesicular liposome architecture—is the proprietary element that determines release kinetics, safety profile, and manufacturability. The FDA label explicitly warns that different formulations of bupivacaine are not bioequivalent even if the milligram strength is the same, and that dosing cannot be converted between formulations . This regulatory position reinforces the technology barrier: a generic entrant must demonstrate not merely chemical equivalence but equivalent release behavior and clinical performance, which requires reverse-engineering a manufacturing process that is itself protected by process patents and trade secrets.

Recent market data confirm the originator’s commercial position. Pacira reported EXPAREL net product sales of USD 147.8 million in Q2 2026, a 3% increase year-over-year, with volume growth of approximately 4% . The company’s full-year 2026 guidance projects EXPAREL net sales of USD 600 million to USD 620 million . The slight gap between volume and revenue growth reflects vial mix and discounting associated with a third group purchasing organization, a dynamic that illustrates the pricing pressure even a differentiated product faces as payer consolidation intensifies.

China Market Dynamics: Generic Entry and Reimbursement-Driven Volume
The China market presents a distinct competitive trajectory. Hengrui’s generic, marketed as 艾恒平®, was approved in November 2022 and entered the National Reimbursement Drug List (NRDL) in 2023 following a significant price reduction . The commercial result was rapid: sales exceeded RMB 170 million in 2024 and surpassed RMB 200 million in the first half of 2025, a year-over-year increase of 456% . This growth trajectory reflects both the expansion of reimbursement coverage and the conversion of a previously inaccessible product into a routinely prescribed option.

The reimbursement terms are specific and consequential. The 2025 NRDL categorizes bupivacaine liposome injection as Class B, with patient cost-sharing set at 5% . The covered indications are: single-dose infiltration for postoperative local analgesia in patients aged 12 and older; interscalene brachial plexus block for postoperative regional analgesia in adults; popliteal sciatic nerve block; and adductor canal block . The inclusion of pediatric patients aged 12 and above is notable—it is the only long-acting local anesthetic in the NRDL with an explicit pediatric indication, a differentiation that expands the addressable population beyond adult surgical patients .

The competitive field in China is expanding. Hunan Kelun received approval in October 2024, becoming the second domestic product, with initial approval covering the infiltration and interscalene block indications . Zhejiang Sundoc Pharmaceutical received approval in July 2026 for its version, with both 10ml:133mg and 20ml:266mg specifications covering infiltration and multiple nerve block indications .齐鲁制药’s application is under review, with approval potentially making it the third or fourth domestic entrant . The entry of multiple generics into a market where the originator has not launched creates an unusual dynamic: price competition is occurring among generic manufacturers before the originator establishes a commercial presence, which may compress margins earlier than in typical generic entry scenarios.

Key Drivers and Clinical Adoption Factors
Opioid-Sparing Imperative: The clinical and policy emphasis on reducing postoperative opioid exposure drives demand for long-acting local anesthetics. A single injection that provides three days of analgesia without a catheter or pump simplifies pain management and reduces the infrastructure burden on surgical units.

Procedural Volume Growth: With aging populations and increasing surgical volumes globally, the demand for long-term, sustained, and safe postoperative pain relief drugs is growing. China’s aging population and steadily increasing number of surgical patients create particularly favorable conditions for adoption .

Reimbursement Expansion: Coverage decisions determine whether the product’s price premium is absorbed by payers or by patients. In the US, Pacira reported separate reimbursement for more than 150 million covered lives as of Q2 2026, approximately half of medically insured lives, with a year-end target of 160 million . In China, NRDL inclusion at 5% patient cost-sharing removed the primary affordability barrier.

Formulation Convenience: The elimination of catheters and pain pumps reduces equipment costs and nursing burden, a factor that matters more in outpatient and ambulatory surgery settings than in inpatient hospital care.

Exclusive Observation: The Generic Wave Is a Formulation Manufacturing Test, Not a Price War
A conventional reading of the bupivacaine liposome injection market treats the entry of Chinese generics as the beginning of a standard price erosion cycle: originator loses share, generics compete on price, margins compress. This framing misidentifies the barrier that has protected the product and, consequently, misjudges how the competitive dynamic will unfold.

The barrier is not the bupivacaine molecule; it is the multivesicular liposome manufacturing process. DepoFoam particles are not simple unilamellar vesicles; they are microscopic spheres with multiple internal chambers separated by lipid membranes, engineered to achieve a specific release profile. Manufacturing them requires precise control of lipid composition, particle size distribution, drug loading, and sterility—variables that are difficult to characterize fully in a regulatory filing and even more difficult to reproduce consistently at commercial scale. A generic entrant that achieves approval has demonstrated that it can manufacture a product that the regulatory authority accepts as equivalent; it has not necessarily demonstrated that it can manufacture it at a cost structure that supports aggressive pricing.

This distinction explains why the Chinese generic market has developed more slowly than a conventional small-molecule generic wave would suggest. Hengrui’s 456% growth was driven by reimbursement expansion and market creation, not by undercutting an incumbent—the originator had not launched in China. Kelun’s entry and Sundoc’s approval add capacity, but each entrant must operate a complex manufacturing process that does not benefit from the scale economies of conventional injectable production. The competitive contest will therefore be determined by manufacturing yield and process reliability, not by the ability to shave price per unit.

The strategic implication is that the originator’s position in markets where it operates—particularly the US—is more durable than the generic entry headlines suggest. Pacira’s 2026 guidance of USD 600–620 million in EXPAREL sales reflects a product that is growing, not declining, despite the presence of a Hengrui generic approved for the US market. The US market’s reimbursement structure, with separate payment outside the surgical bundle for a growing share of covered lives, insulates the product from the commodity pricing dynamics that govern conventional generic injectables. The generic threat is real in China, where NRDL pricing governs access, but it is a different competitive game than the one the originator faces in its home market.

Outlook
The bupivacaine liposome injection market trajectory through 2030 is defined by procedure volume growth, reimbursement expansion, and the gradual entry of generic competitors in price-sensitive markets. The 8.60% CAGR reflects steady adoption in established markets and rapid volume growth in China from a small base. The US market will remain dominated by Pacira, protected by reimbursement structure and the manufacturing complexity of the DepoFoam formulation. The China market will become increasingly competitive as Kelun, Sundoc, and potentially齐鲁 establish positions, with pricing pressure concentrated in the NRDL framework. The competitive frontier lies in manufacturing yield and process reliability, not in the bupivacaine molecule itself. The entrants that master multivesicular liposome production at commercial scale will capture the volume; those that cannot will find that regulatory approval is a necessary but insufficient condition for commercial success.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp